PMID- 23990187
OWN - NLM
STAT- MEDLINE
DCOM- 20160114
LR  - 20161125
IS  - 1898-018X (Electronic)
IS  - 1898-018X (Linking)
VI  - 21
IP  - 1
DP  - 2014
TI  - Late gadolinium enhancement is common in patients with hypertrophic 
      cardiomyopathy and no clinical risk factors for sudden cardiac death: A single 
      center experience.
PG  - 29-32
LID - 10.5603/CJ.a2013.0115 [doi]
AB  - BACKGROUND: Cardiac magnetic resonance (CMR) is used in the diagnosis and risk 
      stratification of hypertrophic cardiomyopathy (HCM) and can detect myocardial 
      replacement fibrosis (anindependent predictor of adverse cardiac outcomes) using 
      late gadolinium enhancement (LGE). METHODS: We retrospectively analysed CMR 
      studies carried out over a 2 year period identifying those which were diagnostic 
      of HCM. 117 cases were analysed. Mean age of subjects was 53 years and 78 (67%) 
      were male. Mean ejection fraction (EF) was 68.3% with a mean left ventricular 
      (LV) mass index of 89.4 g/m(2). Hypertrophy was predominantly asymmetric in 94 
      (80%). RESULTS: All subjects received gadolinium and 80 (68%) had evidence of 
      LGE. LVEF was lower (67 vs. 71%; p = 0.015) and LV mass index higher (94 vs. 81 
      g/m(2); p = 0.007) in the LGE group. The proportion of patients with at least 1 
      clinical risk factor for sudden cardiac death (SCD) was similar in groups with 
      and without LGE (48% vs. 32%; p = 0.160). In this study, a significant proportion 
      (62%) of patients without clinical risk factors for SCD were found to have LGE on 
      CMR. These patients would not currently be considered for therapy with an 
      implantable cardiac defibrillator. CONCLUSIONS: 1. Patients with HCM are at 
      increased risk of SCD, but identifying patients who may benefit from implantable 
      defibrillators is difficult. 2. LGE is associated with adverse cardiovascular 
      outcomes in HCM, but is present in a large proportion of patients. 3. Many 
      patients without clinical risk factors for SCD have LGE and would not currently 
      be considered for an implantable cardiac device.
FAU - Lyons, Kristopher S
AU  - Lyons KS
AD  - Cardiology Department, Royal Victoria Hospital Belfast, United Kingdom. 
      kristopherlyons@hotmail.co.uk.
FAU - Dixon, Lana J
AU  - Dixon LJ
FAU - Johnston, Nicola
AU  - Johnston N
FAU - Noad, Rebecca
AU  - Noad R
FAU - Hamilton, Andrew
AU  - Hamilton A
FAU - McKeag, Nick
AU  - McKeag N
FAU - Horan, Paul
AU  - Horan P
LA  - eng
PT  - Journal Article
DEP - 20130830
PL  - Poland
TA  - Cardiol J
JT  - Cardiology journal
JID - 101392712
RN  - 0 (Contrast Media)
RN  - 0 (Organometallic Compounds)
RN  - 15G12L5X8K (gadobenic acid)
RN  - 6HG8UB2MUY (Meglumine)
RN  - AU0V1LM3JT (Gadolinium)
SB  - IM
MH  - Cardiomyopathy, Hypertrophic/complications/*diagnosis
MH  - Contrast Media
MH  - Death, Sudden, Cardiac/epidemiology/*etiology
MH  - *Delayed Diagnosis
MH  - Female
MH  - Follow-Up Studies
MH  - Gadolinium
MH  - Heart Septum/*pathology
MH  - Humans
MH  - Incidence
MH  - Magnetic Resonance Imaging, Cine/*methods
MH  - Male
MH  - Meglumine/*analogs & derivatives
MH  - Middle Aged
MH  - *Organometallic Compounds
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Survival Rate/trends
MH  - Time Factors
MH  - United Kingdom/epidemiology
EDAT- 2013/08/31 06:00
MHDA- 2016/01/15 06:00
CRDT- 2013/08/31 06:00
PHST- 2013/03/03 00:00 [received]
PHST- 2013/08/09 00:00 [accepted]
PHST- 2013/08/01 00:00 [revised]
PHST- 2013/08/31 06:00 [entrez]
PHST- 2013/08/31 06:00 [pubmed]
PHST- 2016/01/15 06:00 [medline]
AID - VM/OJS/J/28465 [pii]
AID - 10.5603/CJ.a2013.0115 [doi]
PST - ppublish
SO  - Cardiol J. 2014;21(1):29-32. doi: 10.5603/CJ.a2013.0115. Epub 2013 Aug 30.